Pallas Capital Advisors LLC Acquires New Shares in IQVIA Holdings Inc. $IQV

Key Points

• Pallas Capital Advisors acquired 8,032 IQVIA shares worth approximately $1.55 million during the second quarter. Institutional investors collectively own 89.62% of the company.
• IQVIA exceeded quarterly expectations, reporting $3.15 in earnings per share and $4.37 billion in revenue, with revenue up 8.7% year over year. The company also authorized a $2 billion share buyback, representing up to 6.8% of outstanding shares.
• Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $241.88; several firms recently raised their targets to between $247 and $285.

Pallas Capital Advisors LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 8,032 shares of the medical research company's stock, valued at approximately $1,552,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Financial Freedom LLC bought a new stake in IQVIA during the 1st quarter valued at $25,000. Ascentis Independent Advisors acquired a new position in shares of IQVIA during the first quarter worth $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the fourth quarter valued at about $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA during the 4th quarter valued at approximately $27,000. Finally, CrossGen Wealth LLC purchased a new position in shares of IQVIA in the fourth quarter worth about $28,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

NYSE IQV opened at $241.09 on Tuesday. The stock has a market cap of $39.68 billion, a PE ratio of 29.91, a P/E/G ratio of 2.01 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $251.36. The stock has a fifty day simple moving average of $207.80 and a 200-day simple moving average of $186.72. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA's revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts recently commented on IQV shares. BMO Capital Markets raised their target price on IQVIA from $210.00 to $270.00 and gave the stock an "outperform" rating in a report on Wednesday, July 29th. HSBC reiterated a "buy" rating and set a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. JPMorgan Chase & Co. lifted their price target on IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Royal Bank Of Canada increased their price objective on IQVIA from $221.00 to $247.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. Finally, Mizuho increased their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $241.88.

Insider Buying and Selling

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the company's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the sale, the insider owned 13,312 shares in the company, valued at $3,097,436.16. This represents a 29.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sherbet sold 5,000 shares of the firm's stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 12,913 shares of company stock valued at $3,098,793. Company insiders own 1.70% of the company's stock.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source